Abstract
BACKGROUND As approximately 19% of global deaths are attributable to infectious diseases, early diagnosis of infection is very important to reduce mortality. Traditional infection detection strategies have limited sensitivity, detection range, and turnaround times; a detection technology that can simultaneously detect bacterial and fungal infections within 24 h is urgently need in clinical settings.
METHODS We developed nanopore targeted sequencing (NTS) for same-day simultaneous Diagnosis of fungal and bacterial infections. NTS was developed by amplification of 16s rRNA gene (for bacteria), IST1/2 gene (for fungal), and rpoB (for Mycobacterium spp.) using multiple primers, and sequenced by a real-time nanopore sequencing platform. An in-house bioinformatic analyze pipeline was used to diagnose the infectious pathogens by mapping the sequencing results with the constructed databases.
RESULTS Comparison of 1312 specimens from 1257 patients using NTS and culture method; NTS detected pathogens in 58.71% of specimens from patients, compared to 22.09% detected using the culture method. NTS showed significantly higher sensitivity than culture methods for many pathogens. Importantly, a turnaround time of <24 h for all specimens, and a pre-report within 6 h in emergency cases was possible in clinical practice. Modification of antibiotic therapy and maintenance of original anti-infection regimens in 51.52% (17/33) and 36.36% (12/33) of patients was in accordance with NTS results, and quantitative monitoring of clinical treatment effects was evaluated in four patients by continuous NTS tests.
CONCLUSIONS Application of NTS in clinically detected pathogens can improve targeted antibiotic treatment and therapeutic monitoring.
Competing Interest Statement
Wuhan Dgensee Clinical Laboratory Co., Ltd applied patents based on this novel technology.
Funding Statement
Wuhan Dgensee Clinical Laboratory Co., Ltd supporting this research.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data, models, and code generated or used during the study appear in the submitted article.
Abbreviations
- NTS
- nanopore targeted sequencing
- ITS1/2
- fungal internal transcribed spacers 1 and 2
- ATCC
- the American Type Culture Collection
- MTB
- Mycobacterium tuberculosis
- BALF
- bronchoalveolar lavage fluid
- CFU
- colony-forming units
- RPM
- aligned reads of per million sequence reads
- CSF
- cerebrospinal fluid
- NTM
- Nontuberculous mycobacteria
- PPV
- positive predicted value
- NPV
- negative predicted values
- OP
- opportunistic pathogens
- CO
- commensal bacteria/fungi
